Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi‐Database Cohort Study

OBJECTIVE: While tocilizumab (TCZ) is known to increase low‐density lipoprotein (LDL) cholesterol levels, it is unclear whether TCZ increases cardiovascular risk in patients with rheumatoid arthritis (RA). This study was undertaken to compare the cardiovascular risk associated with receiving TCZ ver...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Arthritis Rheumatol
Asıl Yazarlar: Kim, Seoyoung C., Solomon, Daniel H., Rogers, James R., Gale, Sara, Klearman, Micki, Sarsour, Khaled, Schneeweiss, Sebastian
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley and Sons Inc. 2017
Konular:
Rheumatoid Arthritis
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5573926/
https://ncbi.nlm.nih.gov/pubmed/28245350
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/art.40084
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller